Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study
Authors:
- Dolores RodríguezDRDolores Rodríguez
- Roser LlopRLRoser Llop
- Sebastián VidelaSVSebastián Videla
- Aurema OteroAOAurema Otero
- Thiago CarnavalTCThiago Carnaval
- Violeta PoltorakVPVioleta Poltorak
- Miguel Moya-GuerolaMMMiguel Moya-Guerola
- Cristina Masuet-AumatellCMCristina Masuet-Aumatell
- Soledad RodriguezSRSoledad Rodriguez
- Pilar HereuPHPilar Hereu
Open Access
- 14 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (41) , e30976
Abstract
Aim: Vaccination against SARS-CoV2 has been proposed as a fundamental element for the control of the pandemic. This study aimed to describe the suspected adverse reactions (ADR) reported by vaccinated hospital workers. Methods: A descriptive study of suspected ADR was conducted between January and March 2021. The suspected ADR were identified using a specifically designed electronic form and spontaneous reporting. Data were also collected regarding the characteristics of the professionals, vaccine administered, severity, and outcome of ADR. Results: 8169 professionals received 2 doses of SARS-CoV2 vaccine (6672 Comirnaty® and 1497 Spikevax®) and 894 reports of suspected ADR were reported (762 for Comirnaty® and 132 for Spikevax®), resulting in a cumulative ADR incidence of 10.94% (95%CI: 10.27-11.62). The majority of ADR were reported only after the second dose, 497 (56.2%), while 211 (23.6%) were reported only after the first dose and 186 (21%) after both doses. The symptoms were mostly mild, did not require medical assistance, and disappeared within approximately 3 days. One hundred and seventeen professionals had a history of COVID-19 infection. These studies reported, statistically significant, more suspected ADR after the first dose (42.7%) than those with no history of COVID-19 (20.7%). Among professionals, more ADR occurred after the first dose with the Spikevax® vaccine (41.6%) than with the Comirnaty® vaccine (20.5%). Conclusion: The majority of suspected ADR reported were described in the summary of product characteristics (SmPC). Professionals with a history of COVID-19 reported more suspected ADR after the first dose than did those without a history.Keywords
This publication has 7 references indexed in Scilit:
- COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study SaysFrontiers in Immunology, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Prospects for a safe COVID-19 vaccineScience Translational Medicine, 2020
- Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de FarmacovigilanciaMedicina Clinica, 2016
- Prevalence, risk factors and main features of adverse drug reactions leading to hospital admissionEuropean Journal of Clinical Pharmacology, 2013